A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EZETIMIBE (ZETIA?)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: To evaluate the change in directly measured LDL-c after the addition of ezetimibe to a stable background of HAART and statin therapy for 12 weeks compared with the change in LDL-c after 12 weeks of placebo. To evaluate the safety and tolerability of ezetimibe added to a stable background of HAART and statin therapy. Secondary Objectives: Evaluate the effect of ezetimibe on the following cardiovascular measures: ¿ Total cholesterol ¿ Non-high-density lipoprotein cholesterol (non-HDL-c) ¿ High-density lipoprotein cholesterol (HDL-c) ¿ Triglycerides ¿ C- reactive protein, high sensitivity (hsCRP) ¿ Apolipoprotein B (Apo B)?????